Weiner v. Novartis Pharmaceuticals Corporation

991 F. Supp. 2d 217, 2013 WL 6085599, 2013 U.S. Dist. LEXIS 164836
CourtDistrict Court, District of Columbia
DecidedNovember 20, 2013
DocketCivil Action No. 2007-2108
StatusPublished
Cited by5 cases

This text of 991 F. Supp. 2d 217 (Weiner v. Novartis Pharmaceuticals Corporation) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Weiner v. Novartis Pharmaceuticals Corporation, 991 F. Supp. 2d 217, 2013 WL 6085599, 2013 U.S. Dist. LEXIS 164836 (D.D.C. 2013).

Opinion

MEMORANDUM OPINION

JOHN D. BATES, United States District Judge

Plaintiffs Susan and Peter Weiner bring this action against defendant Novartis Pharmaceuticals Corporation, alleging that Susan Weiner suffered injuries as a result of her treatment with drugs marketed and distributed by Novartis. Before the Court is [7] plaintiffs’ unopposed motion to transfer this case to the Southern District of New York. Upon consideration of the motion, defendant’s consent, applicable law, and the entire record herein, and for the reasons explained below, the Court will grant the motion and transfer this action to the Southern District of New York.

BACKGROUND

The Weiners are residents of New York, New York, in the Southern District of New York. Pis.’ Compl. [ECF No. 1] (“Compl.”) ¶¶ 2-3. The events leading up to this lawsuit occurred in New York and the surrounding area. Pis.’ Renewed Mot. to Transfer [ECF No. 7] (“Pis.’ Mot.”) 1. Novartis is a multinational corporation that markets and distributes Zometa, a drug used to treat diseases that have metastasized to bone, throughout all fifty states and the District of Columbia. Compl. ¶¶ 1, 5, 7. Mrs. Weiner was prescribed, purchased, and was infused with Zometa. Id. ¶ 2. Plaintiffs claim that Zometa caused the bone tissue of Mrs. Weiner’s jaw to die, a painful and disfiguring condition known as osteonecrosis. Id. They further claim that Novartis knew or should have known of this adverse effect, and that it nonetheless continued to market and distribute Zometa. Id. ¶¶ 10-21. Invoking diversity jurisdiction, plaintiffs filed suit in this district on November 21, 2007. Id. ¶ 6. They seek compensatory and punitive damages under a number of different theories, including strict liability, failure to warn, and, in Mr. Weiner’s case, loss of consortium. Id. ¶¶ 22-43. On January 8, 2008, the Judicial Panel on Multidistrict Litigation transferred this case to the Middle District of Tennessee, where hundreds of similar lawsuits have been consolidated to litigate common factual questions more efficiently. See In re Aredia and Zometa Prods. Lia. Litig., No. *220 3:06-md-1760 (M.D.Tenn.2006) (“MDL-1760”); Letter from J.P.M.L. [ECF No. 2], Now that the Panel has remanded the case back to this Court, plaintiffs seek to transfer venue to the Southern District of New York, and Novartis consents to transfer. Conditional Remand Order from J.P.M.L. [ECF No. 4]; Pis.’ Mot.; Def.’s Notice of Consent [ECF No. 9].

STANDARD OF REVIEW

District courts have discretion to transfer a case “[f|or the convenience of parties and witnesses, in the interest of justice ... to any other district or division where it might have been brought.” 28 U.S.C. § 1404(a). 1 Courts assess motions to transfer venue according to an “individualized, case-by-case consideration of convenience and fairness.” Stewart Org., Inc. v. Ricoh Corp., 487 U.S. 22, 29, 108 S.Ct. 2239, 101 L.Ed.2d 22 (1988) (quoting Van Dusen v. Barrack, 376 U.S. 612, 622, 84 S.Ct. 805, 11 L.Ed.2d 945 (1964)). However, “a court may not transfer a case from a plaintiffs chosen forum simply because another forum, in the court’s view, may be superior to that chosen by the plaintiff.” Sierra Club v. Van Antwerp, 523 F.Supp.2d 5, 11 (D.D.C.2007) (internal quotation marks omitted). The moving party bears the initial burden of establishing that transfer is proper. S. Utah Wilderness Alliance v. Lewis, 845 F.Supp.2d 231, 234 (D.D.C.2012).

The threshold requirement of section 1404(a) is met here: the transferee forum is a district “where [the action] might have been brought.” § 1404(a); see Thayer/Patricof Educ. Funding v. Pryor Res., Inc., 196 F.Supp.2d 21, 32 (D.D.C.2002). Venue and jurisdiction are proper in both the Southern District of New York and this district. Novartis is the only defendant, so venue is proper in any district where it is subject to personal jurisdiction. See 28 U.S.C. §§ 1391(b)(1), (c)(2). This Court would likely have personal jurisdiction because Novartis “does business” in this jurisdiction and the exercise of jurisdiction would comport with due process. See Shirlington Limo. & Transp., Inc. v. San Diego Union-Tribune, 566 F.Supp.2d 1, 4-5 (D.D.C.2008) (interpreting D.C.Code § 13-334 as a grant of general jurisdiction). New York would also likely have specific personal jurisdiction over Novartis because that is where Novartis sold the Zometa. See N.Y. C.P.L.R. §§ 302(a)(3). New York also probably has general personal jurisdiction over Novartis because it markets and distributes Zometa in New York. See id. § 302(a)(1). Moreover, Novartis does not object to personal jurisdiction or the propriety of venue in either district, and has arguably consented to both by consenting to this section 1404(a) motion, the predicate of which is proper venue in both the transferor and transferee fora. See Freeman v. Bee Mach. Co., 319 U.S. 448, 453, 63 S.Ct. 1146, 87 L.Ed. 1509 (1943) (”[V]enue [is] a personal privilege which may be lost ... by submission through conduct.”) (internal quotation marks omitted). Neither party disputes that the action could have been brought in either district.

*221 In deciding whether the “convenience of parties and witnesses” and “the interest of justice” warrant transfer, courts have identified several relevant factors. Mirroring the statutory language, these factors fall under two broad headings, private-interest factors and public-interest factors. See Trout Unlimited v. U.S. Dep’t of Agric., 944 F.Supp. 13, 16 (D.D.C.1996). “[I]f the balance of private and public interests favors a transfer of venue, then a court may order a transfer.” Montgomery v. STG Int'l, Inc., 532 F.Supp.2d 29, 32 (D.D.C.2008). .

A. Private-interest Factors

In determining whether “the convenience of parties and witnesses” favors transfer, courts consider the following private-interest factors: (1) the plaintiffs choice of forum; (2) the defendant’s choice of forum; (3) whether the claim arose elsewhere; (4) the convenience of the parties; (5) the convenience of the witnesses, particularly if important witnesses may actually be unavailable to give live trial testimony in one of the districts; and (6) the ease of access to sources of proof. Id. at 32-33; see Trout Unlimited, 944 F.Supp. at 16. The Court will consider each factor in turn.

1.Plaintiffs’ forum choice favors transfer

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gray v. Mayorkas
District of Columbia, 2024
Aguilar v. Michael & Son Servs., Inc.
292 F. Supp. 3d 5 (D.C. Circuit, 2017)
Aguilar v. Michael & Son Services, Inc.
District of Columbia, 2017
Hispanic Affairs Project v. Perez
District of Columbia, 2016
Renchard v. Prince William Marine Sales, Inc.
28 F. Supp. 3d 1 (District of Columbia, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
991 F. Supp. 2d 217, 2013 WL 6085599, 2013 U.S. Dist. LEXIS 164836, Counsel Stack Legal Research, https://law.counselstack.com/opinion/weiner-v-novartis-pharmaceuticals-corporation-dcd-2013.